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Introduction: The coexistence of different molecular types of classical protease-resistant prion protein in the same
individual have been described, however, the simultaneous finding of these with the recently described
protease-sensitive variant or variably protease-sensitive prionopathy has, to the best of our knowledge, not yet
been reported.
Case presentation: A 74-year-old Caucasian woman showed a sporadic Creutzfeldt–Jakob disease clinical
phenotype with reactive depression, followed by cognitive impairment, akinetic-rigid Parkinsonism with
pseudobulbar syndrome and gait impairment with motor apraxia, visuospatial disorientation, and evident frontal
dysfunction features such as grasping, palmomental reflex and brisk perioral reflexes. She died at age 77.
Neuropathological findings showed: spongiform change in the patient’s cerebral cortex, striatum, thalamus and
molecular layer of the cerebellum with proteinase K-sensitive synaptic-like, dot-like or target-like prion protein
deposition in the cortex, thalamus and striatum; proteinase K-resistant prion protein in the same regions; and
elongated plaque-like proteinase K-resistant prion protein in the molecular layer of the cerebellum. Molecular
analysis of prion protein after proteinase K digestion revealed decreased signal intensity in immunoblot, a
ladder-like protein pattern, and a 71% reduction of PrPSc signal relative to non-digested material. Her cerebellum
showed a 2A prion protein type largely resistant to proteinase K. Genotype of polymorphism at codon 129 was
valine homozygous.
Conclusion: Molecular typing of prion protein along with clinical and neuropathological data revealed, to the best
of our knowledge, the first case of the coexistence of different protease-sensitive prion proteins in the same patient
in a rare case that did not fulfill the current clinical diagnostic criteria for either probable or possible sporadic
Creutzfeldt–Jakob disease. This highlights the importance of molecular analyses of several brain regions in order to
correctly diagnose rare and atypical prionopathies.
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Prion diseases are fatal neurodegenerative disorders
characterized by the accumulation of the abnormal iso-
form of the cellular prion protein (PrP). The main differ-
ences between the normal physiological and the
abnormal pathologic protein are their physical and
chemical properties, and specifically their detergent
solubility, α-helix and β-sheet content in the secondary
structure, and degree of resistance to protease digestion.
A novel form of sporadic prion disease, termed vari-
ably protease-sensitive prionopathy (PSPr or VPSPr), has
recently been reported [1]. This form comprises, to date,
a low number of cases worldwide [1-6], and in the USA
it was estimated to account for 3% of sporadic Creutz-
feldt–Jakob disease (sCJD) [1]. However, it must be con-
sidered that some cases might have been initially
misdiagnosed as other prion disease phenotypes such as
sCJD [2,5] or atypical forms of Alzheimer’s disease or
Gerstmann–Sträussler–Scheinker syndrome [4], and that
the real prevalence could be higher because PSPr cases
may be misclassified within the group of non-
Alzheimer’s dementias [1]. In this novel sCJD variant,
cases with the three affected 129 polymorphism geno-
types were described [4-6] in which all the distinguishing
properties of higher PrP sensitivity to proteinase K (PK)
degradation and ladder-like band pattern on western
blots were shown.
A common observation in sCJD is the coexistence of
different PrP classical PK-resistant types in the same or
in distinct brain regions [7-15]. However, to the best of
our knowledge, the coexistence of different resistance
PrP types in the same patient with PSPr has not yet been
reported [1,2,4,6].
Here, we describe the first case of sCJD 129VV with
coexistence of different protease-sensitive PrP types.
Case presentation
Clinical history
A 74-year-old Caucasian woman had a 36-month history
of initial depression and a slow progressive cognitive im-
pairment. Past medical history reported hypertension
and cataract surgery. No information about family his-
tory of dementia was recorded. Nine years ago, in the
mourning for the deaths of her spouse and other rela-
tives, she developed a depressive disorder which was
considered reactive and was left untreated. During the
following months she showed bradypsychia and speech
impairment without behavior disorder or evident mem-
ory loss. Ten months later, while still autonomous and
able to take care of her grandchildren, she went for the
first time to a neurologist. The neurological examination
disclosed a bradypsychia, a depressive facies and a
slightly dysarthric, monotonous and dysprosodic speech.
She was cooperative, oriented with respect to time andspace but she followed the instructions clumsily. She
was unable to write (she was low-literate) and presented
gesture ideomotor apraxia that her anxiety made difficult
to examine. Akinetic-rigid syndrome or fasciculations
were absent. The overall examination revealed nothing
but a systolic aortic murmur.
The patient’s clinical picture was interpreted as a re-
active depression in addition to an isolated language dis-
order characterized as pseudobulbar speech that led to
the presumptive diagnosis of a frontal degenerative dis-
order diagnosis. Neither Parkinson’s disease with cogni-
tive impairment, nor Alzheimer’s disease was suspected
at that time. Cardinal features of progressive supra-
nuclear palsy or motor neuron disease were absent.
Additional studies included a cranial MRI showing atro-
phy of the bilateral frontoparietal and cerebellar hemi-
spheres, laboratory tests for B12 vitamin, folic acid and
thyroid hormone levels with normal results, as well as
an echocardiograph showing mild aortic insufficiency.
Treatment with paroxetine (20mg/day) was initiated.
After a month, a new examination revealed worsening of
the language impairment. The patient’s clinical picture
matched with a progressive degenerative cognitive im-
pairment and hence the suspicion of Alzheimer’s disease
or frontotemporal dementia was raised. During the fol-
lowing months, the disease progressed, affecting gait and
causing several falls that included a broken humerus six
months later. A cranial single-photon emission com-
puted tomography performed at that time demonstrated
frontal hypocaptation more prominent on the left that
extended to both temporal lobes. The first electroen-
cephalography (EEG), performed three months after ini-
tial consultation, was normal and a second EEG, five
months later, revealed generalized slow activity. Then
the patient abruptly worsened showing akinetic-rigid
Parkinsonism with pseudobulbar syndrome and gait im-
pairment with motor apraxia, visuospatial discoordina-
tion and evident frontal dysfunction features such as
grasping, palmomental reflex and brisk perioral reflexes.
Sensory examination could not be performed at that
time. Differential diagnosis included dementia with Lewy
bodies, corticobasal ganglionic degeneration, or prion
disease. The patient was hospitalized to perform a lum-
bar puncture; examination of her cerebrospinal fluid
showed two cells with normal biochemical and micro-
biologic parameters including negative 14-3-3 test, ser-
ology against Borrelia burgdorferi and Rapid Plasma
Reagin (RPR) test. From then on for the next 25 months
the patient was hospitalized at home. She was then taken
to hospital due to pneumonia. At that time she was to-
tally dependent with incontinence and an akinetic-
mutism-like syndrome. She died two months later.
Informed consent was obtained from the patient’s rela-
tives for autopsy.
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and samples from nine locations were taken in duplicate
for histopathology and molecular processing. Briefly,
each sample was fixed in 4% formalin, treated withFigure 1 (See legend on next page.)formic acid and embedded in paraffin. Sections were
stained with hematoxylin and eosin or processed for PrP
immunohistochemistry with and without PK pretreat-
ment. Frozen non-fixed samples were submitted to
(See figure on previous page.)
Figure 1 Immunohistological (A-L) and immunoblotting (M-N) results. A–C: frontal cortex; D–F: temporal cortex; G–L: cerebellum.
Spongiform change in the frontal (A) and temporal (D) cortex and molecular layer of the cerebellum (G, H) is accompanied by moderate
neuronal loss in cortex (A, D) and torpedoes in the granular layer of the cerebellum (I). PrP-immunoreactive (PrP-ir) deposits are seen in the
cerebral cortex and cerebellum (B, E, J). PrP-ir is largely reduced in the cerebral cortex after proteinase K (PK) treatment, except for small PrP-ir
dots following a dot-like or target-like pattern (C, F). By contrast, PrP-ir in the molecular layer of the cerebellum, in the form of elongated plaque-
like deposits, is preserved after PK treatment (K, L); PrP plaques in the granular layer are absent. Paraffin sections: A, D, G, H: hematoxylin and
eosin staining; I: phosphorylated neurofilament immunohistochemistry; B, C, E, F, J–L: PrP immunostaining (3F4 antibody) without (B, E, J) and
with (C, F, K, L) PK treatment. A, D, G, J, K, L: × 200 (bar in L, 100μm); B, C, E, F, H, I: × 400 (bar in I, 50μm). PK was used according to the
indications of the supplier: 1 drop of PK concentrate (DAKO, S2019) in 1.6mL of DAKO ChemMate TM PK diluent (S2032) for 15 minutes.
M: Routine immunoblotting conditions (10% brain homogenate and final PK concentration of 440μg/mL) as described elsewhere [5] and five
minutes of film exposure time. PK pretreated brain regions corresponded to occipital cortex (lane 1), putamen/globus pallidus (lane 2),
cerebellum (lane 3), parietal cortex (lane 4), thalamus (lane 5), frontal cortex (lane 6), temporal cortex (lane 7), sporadic Creutzfeldt–Jakob disease
(sCJD) VV2 reference case occipital cortex (lane 8). N: Immunoblotting of PK pretreated samples with less stringent conditions (TeSeE® Western
Blot Kit, Bio-Rad) and detection with 3F4 antibody (Dako, dilution 1:3000) as previously described [5] at ten minutes film exposure time. Brain
regions corresponded to occipital cortex (lane 1), cerebellum (lane 2), parietal cortex (lane 3), thalamus (lane 4), frontal cortex (lane 5), temporal
cortex (lane 6), variably protease-sensitive prionopathy 129MV parietal cortex (lane 7) [5] and sCJD VV2 reference case frontal cortex (lane 8).
Molecular weight standards are indicated in kDa: (M) SDS-PAGE Standards, broad range, Bio-Rad and (N) Precision Plus Protein Unstained
Standards, Bio-Rad.
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comparative enzyme-linked immunosorbent assay
(ELISA) for PK-sensitivity analyses were performed as
described previously [5].
Neuropathology
Spongiform change was found in the upper (Figure 1A)
and inner (Figure 1D) layers of the cerebral cortex, in-
cluding frontal and temporal cortex, entorhinal cortex
and subiculum. The striatum and thalamus showed
moderate spongiform change. PrP immunoreactivity fol-
lowed a synaptic pattern and was accompanied by dot-
like (target-like according to the nomenclature of Zou et
al. [6]) deposits, particularly in the deep cortical layers.
PrP deposition was largely sensitive to PK treatment, ex-
cept for the majority of target-like deposits that were
PK-resistant (Figure 1B, 1C, 1E, 1F). Perineuronal PrP-
immunoreactive deposition was absent.
The cerebellum showed spongiform change in the
molecular layer, moderate loss of Purkinje cells and oc-
casional axonal torpedoes (Figure 1G–I). PrP immuno-
histochemistry showed elongated plaque-like deposits in
the molecular layer which were resistant to PK pretreat-
ment (Figure 1J–L). Plaque-like deposits in the granular
layer of the cerebellum as are often seen in sCJD VV2
were absent.
Accompanying findings were neurofibrillary tangles in
the entorhinal cortex, subiculum, hippocampus, inferior
temporal cortex, and rarely in the frontal cortex, and β-
amyloid plaques, diffuse and neuritic, in the cerebral
cortex corresponding to Alzheimer’s disease-related
changes in neuritic stages VB of Braak.
PRNP analysis
The entire PRNP open reading frame was amplified by
polymerase chain reaction (PCR ) using genomic DNAextracted from fresh brain tissue. PCR was carried out in
a final volume of 25μl with 45ng DNA, 0.1mM dNTP,
1mM MgCl2, 0.2μM of each primer (Forward: 50-
CCATTGCTATGCACTCATTC-30; Reverse: 50-CGGGA-
CAAAGAGAGAAGAAA-30), 0.2mg/ml bovine serum al-
bumin BSA, 0.5 units of Taq Polymerase and 1x Taq
buffer, under the following conditions: initial denaturation
step at 95°C for ten minutes, 35 cycles of denaturation at
95°C for 45 seconds, annealing at 60°C for 30 seconds
and elongation at 72°C for one minute, and a final elong-
ation step at 72°C for ten minutes. Sequence analysis was
done directly by automated sequencing. The patient was
homozygous for valine at codon 129 of PRNP and no
mutations, insertions or silent polymorphisms were
found.Biochemistry and western blotting
Routine immunoblot examinations [5] revealed lack of
signal in all brain regions and a weak three band pattern
of pathogenic PrP in the cerebellum corresponding to a
2A protein type (Figure 1M). The recent description of a
case of protease-sensitive prionopathy 129MV and the
use of technologies based on PrP detection without pro-
teinase K treatment [5] allowed us to reanalyze this case.
Immunoblotting under less restrictive conditions [5] and
incubation with 3F4 antibody revealed a ladder-like PrP
pattern in all brain regions excluding the cerebellum,
which maintained the three band pattern typical of sCJD
type 2A (Figure 1N). The evaluation of PrP PK sensitiv-
ity in the comparative ELISA showed a PrP mean signal
detection rate decreased by 71% [5]. The highest values
ranged from 72% to 78% for cortex, striatum and thal-
amus, and the lowest value of 43% corresponded to the
cerebellum. This could partially explain the absence of
protein signal in immunoblot in the aforementioned
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cerebellum.
Conclusion
The first 129VV protease-sensitive prionopathy series
reported [1] and further characterized (PSPr or VPSPr)
[2,4,6] presented with neurobehavioral and psychiatric
signs such as behavior and mood changes, speech deficit
and cognitive impairment, followed by progressive
motor decline and dementia. We describe the first Span-
ish patient with findings comparable to the cases previ-
ously described [1,2,4,6]. Furthermore, molecular typing
of PrP in different regions of the encephalon (excepting
cerebellum) showed a ladder-like pattern ranging from 29
to 7kDa similar to that found in the 129VV PSPr cases
[1,2,4,6]. However, a striking observation of this case was
that PrP type in the cerebellum was reminiscent of sCJD
type VV2 because PrP-resistant elongated deposits were
present in the molecular layer plaques but absent in the
granular layer. Reanalysis of different brain homogenates
confirmed this finding. Co-occurrence of different PK-
sensitivity PrP types in the same PSPr patient has, to the
best of our knowledge, not yet been reported [1,2,4,6],
even though coexistence of different classical PK-resistant
PrP forms is a common finding in other prion diseases
[7-15]. This observation constitutes a novel finding
which broadens the spectrum of molecular and clinico-
pathological features of spongiform encephalopathies.
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